{
  "$schema": "folio-library-entry/v1",
  "id": "10665-360869",
  "blocks": [
    {
      "id": "library/10665-360869/blocks/prose-sec-front-matter",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Front matter",
      "pageStart": 1,
      "pageEnd": 7,
      "target": "../sections/sec-front-matter.md",
      "narrative": null,
      "content": "GUIDELINES ON \nLONG-ACTING \nINJECTABLE \nCABOTEGRAVIR FOR \nHIV PREVENTION\nGUIDELINES ON \nLONG-ACTING \nINJECTABLE \nCABOTEGRAVIR FOR \nHIV PREVENTION\nGuidelines on long-acting injectable cabotegravir for HIV prevention\nISBN 978-92-4-005409-7 (electronic version) \nISBN 978-92-4-005410-3 (print version)\n© World Health Organization 2022\nSome rights reserved. This work is available under the Creative Commons Attribution-\nNonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/\nlicenses/by-nc-sa/3.0/igo). \nUnder the terms of this licence, you may copy, redistribute an",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "The front matter of WHO's 2022 guidelines on long-acting injectable cabotegravir for HIV prevention, with ISBNs, the CC BY-NC-SA 3.0 IGO licence, suggested citation and disclaimers. It also includes the table of contents and a list of web annexes with links, such as the systematic reviews, modelling, provider survey and evidence-to-decision table.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360869/blocks/prose-sec-000",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Acknowledgements",
      "pageStart": 7,
      "pageEnd": 9,
      "target": "../sections/sec-000-acknowledgements.md",
      "narrative": null,
      "content": "The World Health Organization (WHO) gratefully acknowledges the contributions of many \nindividuals and organizations to these guidelines for the use of long-acting injectable cabotegravir \nfor HIV prevention.\nGuideline Development Group\nCo-chairs: Elizabeth Irungu (Jhpiego, Kenya) and Danvic Rosadiño (LoveYourself, Philippines).\nMax Appenroth (Global Action for Trans Equality, Germany), Connie Celum, (University of \nWashington, United States of America (USA)), Mohamed Chakroun (University Hospital Monastir, \nTunisia), Thato Chidarikire (National Department of Health, South Africa), Olga Denisi",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Acknowledges contributors to the guidelines on long-acting injectable cabotegravir, naming the Guideline Development Group co-chaired by Elizabeth Irungu and Danvic Rosadiño and other members, reviewers and WHO staff. It notes funding from PEPFAR, USAID, Unitaid and the Bill & Melinda Gates Foundation.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360869/blocks/prose-sec-001",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Abbreviations and acronyms",
      "pageStart": 9,
      "pageEnd": 10,
      "target": "../sections/sec-001-abbreviations-and-acronyms.md",
      "narrative": null,
      "content": "AIDS\t\nacquired immunodeficiency syndrome\nART\t\nantiretroviral therapy\nARV\t\nantiretroviral\nCAB\t\ncabotegravir\nCAB-LA\t\nlong-acting injectable cabotegravir\nDTG\t\ndolutegravir\nDVR\t\ndapivirine vaginal ring\nFTC\t\nemtricitabine\nGDG\t\nGuideline Development Group \nGRADE\t\nGrading of Recommendations, Assessment, Development and Evaluation\nHBsAg\t\nhepatitis B surface antigen\nHBV\t\nhepatitis B virus\nHCV\t\nhepatitis C virus\nHIV\t\nhuman immunodeficiency virus\nINSTI\t\nintegrase strand transfer inhibitor\nISR\t\ninjection site reaction\nLMIC\t\nlow- and middle-income country\nMPT\t\nmulti-purpose prevention technology\nNAT\t\nnucle",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "A list of abbreviations and acronyms used in the cabotegravir guidelines, such as CAB-LA, DVR, GRADE, PrEP and TDF.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360869/blocks/prose-sec-002",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Definitions of key terms",
      "pageStart": 10,
      "pageEnd": 11,
      "target": "../sections/sec-002-definitions-of-key-terms.md",
      "narrative": null,
      "content": "Age groups\nIn these guidelines the following definitions for adults, adolescents, children and infants are \nused in recommendations for specific age groups. It is acknowledged that countries may have \nother definitions under national laws.\n•\tAn adult is a person older than 19 years of age.\n•\tAn adolescent is a person 10–19 years of age inclusive.\n•\tA child is a person from one year of age to younger than 10 years of age.\n•\tAn infant is a child younger than one year of age.\nKey populations\nKey populations are defined as groups who, due to specific higher-risk behaviours, are at \nincreased risk",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Defines key terms used in the guidelines, including age groups for adults, adolescents, children and infants and WHO's definition of key populations. It also explains concepts such as substantial risk of HIV and notes that risk-informed PrEP can be cost-effective but that cost should not be the only consideration.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360869/blocks/prose-sec-003",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Executive summary",
      "pageStart": 11,
      "pageEnd": 11,
      "target": "../sections/sec-003-executive-summary.md",
      "narrative": null,
      "content": "",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "empty"
      }
    },
    {
      "id": "library/10665-360869/blocks/prose-sec-004",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Purpose",
      "pageStart": 11,
      "pageEnd": 11,
      "target": "../sections/sec-004-purpose.md",
      "narrative": null,
      "content": "Achieving the Global AIDS target for 2025 of ensuring that 95% of people at risk of HIV \nacquisition have access to HIV prevention options requires a focus on expanding effective HIV \nprevention choices. Pre-exposure prophylaxis (PrEP) is a key component of combination HIV \nprevention. In 2015 the World Health Organization (WHO) recommended oral PrEP containing \ntenofovir disoproxil fumarate (TDF) for people at substantial risk of HIV (1) and, in 2021, \nrecommended the dapivirine vaginal ring (DVR) for cisgender women at substantial risk of HIV \n(2). Although expansion of access to and uptake",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Explains that reaching the 2025 target of 95% access to HIV prevention requires more prevention choices, recalling WHO's 2015 oral PrEP and 2021 dapivirine ring recommendations and slow uptake. It presents the guideline's purpose of recommending long-acting cabotegravir using a public health approach and highlighting implementation considerations.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360869/blocks/prose-sec-005",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Guideline development methodology",
      "pageStart": 11,
      "pageEnd": 12,
      "target": "../sections/sec-005-guideline-development-methodology.md",
      "narrative": null,
      "content": "In response to the availability of new evidence on the efficacy of CAB-LA for the prevention \nof HIV acquisition, external experts and stakeholders proposed to make this recommendation \nas an addition to the HIV prevention recommendations in the 2021 Consolidated guidelines on \nHIV prevention, testing, treatment, service delivery and monitoring (3).\nAs a result, from January to May 2022, the WHO Department of Global HIV, Hepatitis and \nSexually Transmitted Infections Programmes led the development of new guidance with \nsupport from a Guideline Development Group (GDG) and an External Review Gro",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Describes how the cabotegravir recommendation was developed between January and May 2022 by WHO with a Guideline Development Group and External Review Group, based on a PICO question and systematic reviews. It states that the group judged the evidence of moderate certainty and unanimously made a conditional recommendation to offer long-acting cabotegravir as an additional prevention choice.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360869/blocks/prose-sec-006",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Implications for implementation",
      "pageStart": 12,
      "pageEnd": 13,
      "target": "../sections/sec-006-implications-for-implementation.md",
      "narrative": null,
      "content": "CAB-LA should be delivered as an additional \nchoice alongside other PrEP options, \nincluding oral PrEP and the DVR, as part of a \ncomprehensive HIV prevention approach. To \ndate, provision of CAB-LA has largely been \nlimited to trial settings, certain geographies \nand specific populations. This guideline \noutlines operational research needed to \naddress research and implementation gaps, and to inform decisions on how to approach the \nimplementation and scale-up of CAB-LA successfully. The GDG stressed that operational \nresearch – and implementation of services itself – must involve the full pa",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "States that long-acting cabotegravir should be offered alongside oral PrEP and the dapivirine ring within comprehensive prevention, noting that provision has so far been mostly limited to trials. It lists implementation considerations and research needs, such as HIV testing strategies, service delivery models, drug resistance, safety in pregnancy and cost-effectiveness, with full community participation.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360869/blocks/prose-sec-007",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "\u0003Introduction",
      "pageStart": 13,
      "pageEnd": 13,
      "target": "../sections/sec-007-1-introduction.md",
      "narrative": null,
      "content": "",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "empty"
      }
    },
    {
      "id": "library/10665-360869/blocks/prose-sec-008",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "\u0003Background",
      "pageStart": 13,
      "pageEnd": 14,
      "target": "../sections/sec-008-11-background.md",
      "narrative": null,
      "content": "HIV remains a major public health issue, with approximately 37.7 [30.2–45.1] million people \nliving with HIV and 1.5 [1.0–2.0] million new infections in 2020. Despite global commitments \nto reduce new infections by 75% between 2010 and 2020, to fewer than 500 000, new HIV \ninfections declined only by 31% over that decade (4). Key populations1 and their partners \naccounted for 65% of the new infections globally and for 93% of new infections outside sub-\nSaharan Africa. Adolescent girls and young women accounted for 25% of new infections in \nsub-Saharan Africa in 2020, despite constituting just",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Describes the global HIV situation, with about 37.7 million people living with HIV and 1.5 million new infections in 2020, a decline well short of global targets, and high shares among key populations and young women in sub-Saharan Africa. It recalls the 2021 Political Declaration targets and WHO's existing PrEP recommendations. It explains the case for additional PrEP options and notes that risk-informed PrEP can be cost-effective while having value beyond cost.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360869/blocks/prose-sec-009",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "\u0003Objective and intended audience",
      "pageStart": 14,
      "pageEnd": 15,
      "target": "../sections/sec-009-12-objective-and-intended-audience.md",
      "narrative": null,
      "content": "This guideline is intended to provide an evidence-informed recommendation for CAB-LA as \nPrEP for HIV prevention to support countries in achieving national targets of reducing new HIV \ninfections. \nThe primary audience for this guideline is national and subnational programme managers \nand policy-makers responsible for the national health sector response to HIV, particularly in \nLMICs, and clinicians and other health care providers, particularly those working in primary \nhealth services, including lay and community health workers, who are the first point of contact \nfor people who could benefit",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Sets out the objective of providing an evidence-informed recommendation on cabotegravir as PrEP and names the intended audiences, from national programme managers and clinicians in low- and middle-income countries to people at risk, community organizations and donors.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360869/blocks/prose-sec-010",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "\u0003Guiding principles",
      "pageStart": 15,
      "pageEnd": 16,
      "target": "../sections/sec-010-13-guiding-principles.md",
      "narrative": null,
      "content": "The following principles have informed the development of this guideline and should guide the \nimplementation of the recommendations:\n•\tThis guideline needs to be implemented within a public health and universal health coverage \nframework. In addition to strengthening HIV prevention services, the guideline should be \nimplemented with a view to strengthening broader health systems, especially primary and \ncommunity-based health services.\n•\tImplementation of the guideline needs to be accompanied by efforts to promote and protect \nequity and the human rights of people at substantial risk of HIV,",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Lists the guiding principles for implementing the cabotegravir guideline, including a public health and universal health coverage approach, equity and human rights, voluntary and stigma-free services. It also stresses adapting to local context and full participation of affected communities.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360869/blocks/prose-sec-011",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "\u0003Methods for guideline development",
      "pageStart": 16,
      "pageEnd": 17,
      "target": "../sections/sec-011-2-methods-for-guideline-development.md",
      "narrative": null,
      "content": "This guideline was developed in accordance with procedures established by the WHO \nGuidelines Review Committee (16). The recommendation in this guideline is based on the \nGrading of Recommendations Assessment, Development and Evaluation (GRADE) approach \nto reviewing evidence and formulating recommendations (17). Consistent with previous WHO \nguidelines, this guideline is based on a public health approach that considers effectiveness, \nacceptability, feasibility and resource needs across a variety of settings.\nAll external contributors to the development of the guidelines, including members of",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Explains that the guideline followed WHO Guidelines Review Committee procedures and the GRADE approach, with declarations of interest from all external contributors. It lists the web annexes of evidence prepared and presented at meetings facilitated by an independent methodologist.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360869/blocks/prose-sec-012",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "\u0003Rationale and supporting evidence",
      "pageStart": 17,
      "pageEnd": 17,
      "target": "../sections/sec-012-3-rationale-and-supporting-evidence.md",
      "narrative": null,
      "content": "",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "empty"
      }
    },
    {
      "id": "library/10665-360869/blocks/prose-sec-013",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Summary of review findings",
      "pageStart": 17,
      "pageEnd": 20,
      "target": "../sections/sec-013-31-summary-of-review-findings.md",
      "narrative": null,
      "content": "Evidence on the safety, efficacy and effectiveness of CAB-LA was collected in a systematic \nreview of research on CAB-LA (Web Annex B) and from additional unpublished preliminary \nresults from modelling presented to the GDG (18, 19). The systematic review included 12 \neligible articles or conference abstracts reporting data from four studies. Two studies, \nHPTN 083 and HPTN 084, were phase IIb/III studies assessing the efficacy of CAB-LA versus \ndaily tenofovir disoproxil fumarate and emtricitabine (TDF/FTC) oral PrEP (herein referred \nto as “efficacy studies”), while two studies, ECLAIR and H",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Summarizes the systematic review of four randomized trials of long-acting cabotegravir, the efficacy studies HPTN 083 and 084 and the safety studies ECLAIR and HPTN 077, enrolling about 8,120 people. It reports a 79% reduction in HIV risk compared with oral TDF/FTC, largely explained by poor adherence to daily pills, and describes breakthrough and other infections. It reviews modelling for Atlanta, Montreal, South Africa and sub-Saharan Africa on the infections that expanded or switched PrEP could avert. It then covers safety, finding no significant difference in adverse events, limited pregnancy data without congenital abnormalities, and no reported differences in STIs.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360869/blocks/prose-sec-014",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Cost–effectiveness",
      "pageStart": 20,
      "pageEnd": 21,
      "target": "../sections/sec-014-32-costeffectiveness.md",
      "narrative": null,
      "content": "Evidence on cost–effectiveness of CAB-LA was derived from a systematic review (Web Annex \nB) and additional modelling evidence presented to the GDG (Web Annexes D and E) (19, 23). \nThe review identified seven studies that assessed the cost or cost–effectiveness of CAB-LA or \nlong-acting PrEP more generally. Of these, six modelled data and scenarios specific to South \nAfrica (28-33), while one study assessed costs for men who have sex with men and transgender \nwomen in the United States (34). \nResults of the costing studies were mixed. \nSeveral studies found CAB-LA or injectable \nPrEP generally",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Reviews seven costing studies, mostly from South Africa, and new models showing mixed results on whether long-acting cabotegravir is cost-effective. It finds it could be cost-effective in some settings or groups, for example in South Africa if focused on periods of substantial risk and priced within twice the cost of oral PrEP, but not compared with generic oral PrEP in high-income settings.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360869/blocks/prose-sec-015",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Values and preferences",
      "pageStart": 21,
      "pageEnd": 22,
      "target": "../sections/sec-015-33-values-and-preferences.md",
      "narrative": null,
      "content": "Evidence on acceptability, values and preferences for CAB-LA was derived from a systematic \nreview of publications on injectable PrEP (Web Annex C), results of qualitative research from \nfour global key population networks and a study on the perspectives of PrEP providers (Web \nAnnex F).\nA systematic review identified 99 articles \nmeeting inclusion criteria for the values and \npreferences analysis (Web Annex C). Most \nstudies were observational, cross-sectional \nand qualitative in North America, and men \nwho have sex with men were the most \nresearched respondent group. Most studies \nexamined i",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Summarizes evidence on acceptability and preferences from a review of 99 studies, key population networks and a provider survey, showing general interest in injectable PrEP with variation between groups. It notes providers' concerns about cost, workload, testing, drug resistance and stopping the drug, and the potential to overcome adherence problems with daily pills.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360869/blocks/prose-sec-016",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Feasibility",
      "pageStart": 22,
      "pageEnd": 22,
      "target": "../sections/sec-016-34-feasibility.md",
      "narrative": null,
      "content": "Both HPTN 083 and HPTN 084 implemented CAB-LA for PrEP in a range of countries for adult \ncisgender men and transgender women who have sex with men and for cisgender women \nat risk of HIV. No studies have demonstrated the feasibility of this intervention in individuals \nunder the age of 18 years, although studies are ongoing. The RCTs have continued as \nunblinded, open-label extensions, but no study or project has implemented CAB-LA for PrEP \noutside of a clinical trial setting. \nServices for oral PrEP have been demonstrated to be feasible for all populations across regions, \nalthough, for som",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Notes that long-acting cabotegravir has been used only in trials, among adult cisgender women and among cisgender men and transgender women who have sex with men, with no evidence yet for people under 18. It points to experience with oral PrEP and injectable contraceptives and flags the need to explore feasibility for sex workers, people who inject drugs, prisoners and transgender men.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360869/blocks/prose-sec-017",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Equity",
      "pageStart": 22,
      "pageEnd": 22,
      "target": "../sections/sec-017-35-equity.md",
      "narrative": null,
      "content": "HIV prevention among PrEP users will contribute to equitable health outcomes by sustaining \ntheir health and the health of their sexual partners. Access to PrEP also provides opportunities \nfor access to sexual and reproductive health services addressing multiple health needs. \nConsidering the evidence reviewed and its discussions, the GDG noted that offering CAB-LA as \nan additional PrEP option could increase equity by reaching more individuals who could benefit \nfrom PrEP and who would prefer injectable PrEP over other options. However, the GDG noted \nthat inequality in health outcomes could",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "States the guideline group's view that offering cabotegravir could improve equity by reaching more people who prefer injections, but that unequal access between and within countries could widen health inequalities.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360869/blocks/prose-sec-018",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Rationale for recommendation",
      "pageStart": 22,
      "pageEnd": 24,
      "target": "../sections/sec-018-36-rationale-for-recommendation.md",
      "narrative": null,
      "content": "Recommendation\nLong-acting injectable cabotegravir may be offered as an additional prevention choice \nfor people at substantial risk of HIV infection, as part of combination prevention \napproaches (conditional recommendation; moderate certainty of evidence).\nThe GDG agreed that CAB-LA for PrEP could have substantial benefits, a judgment based \non evidence of moderate certainty, as well as on acceptability to stakeholders, feasibility of \nimplementation, potential for cost–effectiveness and potential to improved equity. The GDG \nconsidered the evidence synthesised across the domains described a",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "States the conditional recommendation that people at substantial risk of HIV may be offered long-acting injectable cabotegravir as an extra prevention option, based on moderate-certainty evidence. It explains the group's reasoning about benefits, uncertainties and costs as a barrier, and describes people for whom it may suit, such as those valuing discretion or struggling with oral pills.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360869/blocks/prose-sec-019",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "\u0003Implementation considerations",
      "pageStart": 24,
      "pageEnd": 24,
      "target": "../sections/sec-019-4-implementation-considerations.md",
      "narrative": null,
      "content": "",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "empty"
      }
    },
    {
      "id": "library/10665-360869/blocks/prose-sec-020",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "HIV testing and other testing requirements",
      "pageStart": 24,
      "pageEnd": 26,
      "target": "../sections/sec-020-41-hiv-testing-and-other-testing-requirements.md",
      "narrative": null,
      "content": "As with oral PrEP and the DVR, HIV testing is required before offering CAB-LA and should \nalso be done before each injection while using CAB-LA and, ideally, regularly after CAB-LA \ndiscontinuation. HIV testing can be conducted according to the WHO testing strategy for HIV \ndiagnosis in people >18 months of age, using the national testing algorithm composed of \nquality-assured serology assays (that is, rapid diagnostic tests and enzyme immunoassays). \nOnly individuals who are HIV-negative should be initiated on PrEP. Individuals with one or more \nreactive test results prior to initiating CAB-L",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Sets out HIV testing requirements for cabotegravir, with testing before starting, before each injection and ideally after stopping, using national serology algorithms and further testing for reactive or inconclusive results. It warns that missed or delayed diagnosis during use or in the drug's long pharmacokinetic tail could lead to integrase-inhibitor resistance, and weighs the uncertain benefits, costs and practical limits of adding nucleic acid testing. It also covers hepatitis B and C considerations and states that kidney function monitoring is not required.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360869/blocks/prose-sec-021",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Service delivery",
      "pageStart": 26,
      "pageEnd": 27,
      "target": "../sections/sec-021-42-service-delivery.md",
      "narrative": null,
      "content": "CAB-LA provision to date has been limited to the two RCTs, with some further experience \nemerging from the unblinded open-label extensions of the RCTs. Services for oral PrEP, \nhowever, have been implemented in a range of settings in many countries. These include \nprimary health care clinics, sexual and reproductive health services, ante- and post-natal care \nservices and in community settings through, for example, key population-led clinics and mobile \nclinics. Many of these settings have experience in implementing other types of preventative \nhealth services relevant to the provision of CAB-",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Discusses service delivery for long-acting injectable cabotegravir (CAB-LA) as HIV pre-exposure prophylaxis, noting that experience so far comes mainly from two trials while oral PrEP has been offered in many settings. It suggests that such settings, and PrEP services offering a wider package of care, could support CAB-LA, with meaningful involvement of key populations and young people.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360869/blocks/prose-sec-022",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Comprehensive services",
      "pageStart": 27,
      "pageEnd": 27,
      "target": "../sections/sec-022-43-comprehensive-services.md",
      "narrative": null,
      "content": "PrEP, including CAB-LA, should be provided in combination with other effective and well-\nestablished prevention approaches and health services. Depending on the local context and \nthe needs and preferences of the populations that could benefit from PrEP, this may include the \nprovision of condoms, post-exposure prophylaxis (PEP) for HIV, testing and treatment of STIs \nand viral hepatitis, sexual and reproductive health services, mental health support, services \nthat prevent and protect against gender-based violence, gender-affirming care and harm \nreduction services for people who use drugs (i",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Recommends offering PrEP, including CAB-LA, alongside other prevention and health services such as condoms, PEP, STI and hepatitis care, mental health support, gender-affirming care and harm reduction.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360869/blocks/prose-sec-023",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Offering a choice of PrEP options",
      "pageStart": 27,
      "pageEnd": 27,
      "target": "../sections/sec-023-44-offering-a-choice-of-prep-options.md",
      "narrative": null,
      "content": "People who could benefit from PrEP have diverse HIV prevention needs and preferences, and \nthese may change over time. A range of PrEP options should be available to provide choice \nto people who could benefit from PrEP, including TDF-based oral PrEP, the DVR and CAB-LA. \nPeople interested in PrEP should be provided information on the available options and their \nrelative efficacy and safety and counselled to make an informed decision regarding the best \noption for them.",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Advises that a range of PrEP options, including oral PrEP, the dapivirine ring and CAB-LA, be available, with counselling so people can make an informed choice.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360869/blocks/prose-sec-024",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Involving communities",
      "pageStart": 27,
      "pageEnd": 27,
      "target": "../sections/sec-024-45-involving-communities.md",
      "narrative": null,
      "content": "Meeting the needs of populations at substantial risk of HIV infection and providing PrEP \nservices, including CAB-LA, requires the full participation of communities in developing and \nimplementing programmes. The following are good participatory practices that apply to \nservices for all priority and key populations: \n•\tRecognize the leadership and resilience of priority and key populations in addressing the HIV \nepidemic at both the local and global levels and sustain their participation through adequate \nfunding and support for community-led organizations.\n•\tStrengthen the capacity of communi",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Lists good participatory practices for involving communities in PrEP and CAB-LA programmes, such as funding community-led organizations, building their capacity and expanding community-based services. It also calls for coercion-free choice and for decriminalizing consensual sex, gender expression, sex work and drug use.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360869/blocks/prose-sec-025",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Creating awareness and demand",
      "pageStart": 27,
      "pageEnd": 28,
      "target": "../sections/sec-025-46-creating-awareness-and-demand.md",
      "narrative": null,
      "content": "As CAB-LA is a new PrEP product, many communities and providers have limited or no \nawareness of it. Countries wanting to introduce CAB-LA as an additional HIV prevention \noption should conduct an awareness programme for communities and providers before and \nduring introduction as a first step towards creating demand and enabling people to make \ninformed choices. Engagement with networks of individuals who could benefit from PrEP and \nwith community organizations, including key populations networks, is needed to understand \nconcerns and respond to questions about this new product. Community ac",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Recommends awareness programmes for communities and providers before and during the introduction of CAB-LA, engaging key population networks to build acceptance and demand.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360869/blocks/prose-sec-026",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Adherence support and discontinuation",
      "pageStart": 28,
      "pageEnd": 28,
      "target": "../sections/sec-026-47-adherence-support-and-discontinuation.md",
      "narrative": null,
      "content": "PrEP products, including CAB-LA, should be used during periods of substantial HIV risk and \nmay be stopped if an individual is no longer at risk or decides to use an alternative PrEP \nproduct or HIV prevention strategy. The two RCTs on CAB-LA found CAB-LA highly effective \nat preventing HIV when CAB-LA was administered on time, although a few cases of HIV \nacquisition, despite on-time injections, were observed. Several HIV infections occurred \nwhen injections were delayed and after discontinuation. When a person misses a scheduled \ninjection or discontinues PrEP, CAB concentrations in the body",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Explains that CAB-LA and other PrEP products are meant for times when HIV risk is substantial, and that trial infections occurred mainly with delayed injections or after stopping. It describes the declining protection during the drug's pharmacokinetic tail, the associated resistance risk and counselling on injection-site reactions and other side-effects.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360869/blocks/prose-sec-027",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Training and support for providers",
      "pageStart": 28,
      "pageEnd": 29,
      "target": "../sections/sec-027-48-training-and-support-for-providers.md",
      "narrative": null,
      "content": "As CAB-LA is a new PrEP product, few PrEP providers will have experience delivering CAB-\nLA. However, there is extensive experience with delivering oral PrEP. National programmes \nshould provide training and support to a range of providers in services that may be able to \noffer CAB-LA to clients. Training for providers will include capacity building on discussing HIV \nprevention needs and preferences with clients; assessing the appropriateness of the different \nHIV prevention options available, including CAB-LA, the DVR and oral PrEP regimens; correct \nadministration of CAB-LA; support for saf",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Describes the training providers will need to deliver CAB-LA, building on oral PrEP experience, including discussing prevention preferences, administering injections and offering respectful, non-judgemental services. It anticipates that training needs will become clearer as implementation expands.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360869/blocks/prose-sec-028",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "\u0003Research gaps and needs",
      "pageStart": 29,
      "pageEnd": 29,
      "target": "../sections/sec-028-5-research-gaps-and-needs.md",
      "narrative": null,
      "content": "Operational research is needed to inform decisions on the implementation and scale-up of \nCAB-LA. It is important to partner with communities of populations affected by HIV to identify \npriorities and to inform the design and implementation of research and the monitoring of \noutcomes.",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Calls for operational research, designed with affected communities, to guide CAB-LA implementation and scale-up.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360869/blocks/prose-sec-029",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Providing CAB-LA for key populations",
      "pageStart": 29,
      "pageEnd": 29,
      "target": "../sections/sec-029-51-providing-cab-la-for-key-populations.md",
      "narrative": null,
      "content": "HPTN 083 and HPTN 084 provided PrEP to cisgender men who have sex with men, transgender \nwomen (approximately 2.5% of participants) and cisgender women. However, the studies \nincluded few transgender men and did not specify including non-binary individuals. Further \nresearch is required to evaluate CAB-LA service delivery for trans and gender-diverse people \nand their specific needs and preferences. \nThe trials on CAB-LA have not reported on interactions between gender-affirming hormones \nand CAB-LA. Although interactions are not expected theoretically, this is an area where further \nresearch",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Identifies research gaps for CAB-LA among key populations, noting that trials included few transgender men or non-binary people and no people who use drugs. It highlights needs such as data on gender-affirming hormones, alternative injection sites and monitoring of access barriers.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360869/blocks/prose-sec-030",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "CAB-LA for adolescents under age 18",
      "pageStart": 29,
      "pageEnd": 30,
      "target": "../sections/sec-030-52-cab-la-for-adolescents-under-age-18.md",
      "narrative": null,
      "content": "Individuals under age 18 were not included in ECLAIR, HPTN 077, HPTN 083 or HPTN 084, \nalthough sizable numbers of study participants were under the age of 30. Small numbers \nof adolescents have been included in ongoing sub-studies for HPTN 083 (38) and 084 (39). \nAdditional studies including adolescent and young people are planned. These will contribute \nevidence on CAB-LA safety and acceptability among adolescent men who have sex with men, \nadolescent women, transgender women and gender-nonconforming people.\nYoung people frequently face additional barriers to accessing and effectively using",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Notes that people under 18 were excluded from the main CAB-LA trials and that adolescent studies are planned, calling for operational research on acceptability and support for young people.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360869/blocks/prose-sec-031",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Safety in pregnancy and breastfeeding",
      "pageStart": 30,
      "pageEnd": 30,
      "target": "../sections/sec-031-53-safety-in-pregnancy-and-breastfeeding.md",
      "narrative": null,
      "content": "In some settings pregnancy and the postpartum period are characterized by increased risk of \nacquiring HIV. HIV acquired during pregnancy or breastfeeding is associated with a risk of HIV \ntransmission to the infant. It is important that women of reproductive potential do not face \nbarriers to uptake of effective HIV prevention options such as CAB-LA.\nAll women enrolled in HPTN 084 and HPTN 077 were required to use a long-acting reversible \ncontraceptive. In HPTN 084 women who were pregnant, breastfeeding or wished to become \npregnant were excluded from enrolment. However, in the open-label ex",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Discusses limited data on CAB-LA safety in pregnancy and breastfeeding, noting trial contraception requirements and the open-label extension allowing continued use under monitoring. It calls for further research and links to contraceptive and antenatal services.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360869/blocks/prose-sec-032",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Optimal HIV testing strategies and drug resistance",
      "pageStart": 30,
      "pageEnd": 31,
      "target": "../sections/sec-032-54-optimal-hiv-testing-strategies-and-drug-resis.md",
      "narrative": null,
      "content": "As noted in section 4.1, the optimal HIV testing strategies, testing frequency and general \napproaches throughout CAB-LA implementation remain uncertain and constitute a critical \nresearch gap. Some key issues include (1) risk of delayed HIV diagnosis and treatment, (2) \nimplications for HIV drug resistance, (3) optimal strategies for establishing HIV infection post-\nCAB-LA initiation and (4) feasibility and acceptability of HIV testing approaches and frequency \nin real-world implementation. \n5.4.1 \u0003Delayed diagnosis, drug resistance and impact on treatment \nThere are risks of delayed diagnosi",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Identifies uncertainty about optimal HIV testing strategies during CAB-LA use as a critical research gap, including risks of delayed diagnosis and drug resistance. It calls for studies on testing frequency, alternative assays and cross-resistance between cabotegravir and dolutegravir.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360869/blocks/prose-sec-033",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Service delivery models",
      "pageStart": 31,
      "pageEnd": 32,
      "target": "../sections/sec-033-55-service-delivery-models.md",
      "narrative": null,
      "content": "Oral PrEP has been delivered through a range of services, including services for STIs and \nsexual and reproductive health, antenatal and postnatal care and primary health care, and \nin a range of settings, including clinics, pharmacies and the community. Task sharing among \na range of health care providers, such as nurses and trained lay providers, is playing an \nincreasingly prominent role in the delivery of PrEP. This differentiated PrEP delivery supports \ncomprehensive, person-centred services, adapting them to the needs and preferences of the \npeople who could benefit from PrEP, and suppor",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Notes that oral PrEP is delivered through varied services with task sharing, whereas CAB-LA has so far been used only in trials. It calls for implementation research on offering CAB-LA alongside other options, including different injection schedules, self-injection and community delivery.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360869/blocks/prose-sec-034",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Population-level impact and costs and cost–effectiveness",
      "pageStart": 32,
      "pageEnd": 33,
      "target": "../sections/sec-034-56-population-level-impact-and-costs-and-costeff.md",
      "narrative": null,
      "content": "effectiveness \nPreliminary results of mathematical modelling suggest that increasing the total number of PrEP \nusers, whether of oral PrEP or CAB-LA, has the strongest impact on decreasing HIV incidence \n(Web Annexes D and E) (23). CAB-LA use itself has the potential to increase the number of \nHIV infections averted. Models for sub-Saharan Africa also suggest that CAB-LA could be \ncost-effective even if priced higher than oral PrEP. However, more research on the potential \npopulation-level impact, costs and cost–effectiveness of CAB-LA is needed across settings and \npopulations to develop mode",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Reports preliminary modelling suggesting that expanding total PrEP use has the largest effect on HIV incidence and that CAB-LA could be cost-effective in sub-Saharan Africa, while calling for more realistic models and cost studies.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360869/blocks/prose-sec-035",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "\u0003Updating and dissemination",
      "pageStart": 33,
      "pageEnd": 34,
      "target": "../sections/sec-035-6-updating-and-dissemination.md",
      "narrative": null,
      "content": "This guideline is being launched as a web-based product for dissemination and will include \nall evidence as presented to the GDG (Web Annexes A to F). The guideline will also be \nincorporated into the periodic updates of the WHO consolidated guidelines on HIV (3). The \nconsolidated guidelines on HIV will be updated in full or in part based on regular scoping \nexercises of available evidence and experience from country implementation that trigger and \nguide the need for new guidance. As the evidence base or users’ needs change, consideration \nwill be given to producing technical updates such as",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Describes how the CAB-LA guideline will be published online with its web annexes, incorporated into WHO's consolidated HIV guidelines and disseminated with regional and country offices, with uptake tracked through a country policy database.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360869/blocks/prose-sec-036",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "References",
      "pageStart": 34,
      "pageEnd": 37,
      "target": "../sections/sec-036-references.md",
      "narrative": null,
      "content": "1.\t Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV. \nGeneva: World Health Organization; 2015 (https://apps.who.int/iris/handle/10665/186275, \naccessed 18 May 2022).\n2.\t Guidelines: updated recommendations on HIV prevention, infant diagnosis, antiretroviral \ninitiation and monitoring. Geneva: World Health Organization; 2021 (https://apps.who.int/\niris/handle/10665/340190, accessed 18 May 2022).\n3.\t Consolidated guidelines on HIV prevention, testing, treatment, service delivery and \nmonitoring: recommendations for a public health approach. Geneva: World",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "The reference list for the WHO guidelines on long-acting injectable cabotegravir for HIV prevention, citing WHO HIV guidance, UNAIDS reports and trial registrations.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360869/blocks/prose-sec-037",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Annex 1. \u0003Process for developing the guidelines",
      "pageStart": 37,
      "pageEnd": 40,
      "target": "../sections/sec-037-annex-1-process-for-developing-the-guidelines.md",
      "narrative": null,
      "content": "ANNEX. \u0003PROCESS FOR DEVELOPING  \nTHE GUIDELINES\nMethods for synthesizing evidence\nWHO’s Department of Global HIV, Hepatitis and STI Programmes developed this guideline \naccording to WHO standards and requirements for guideline development, 2nd edition, 2014 \n(1) and under the oversight of the WHO Guideline Review Committee.\nThe Secretariat within the WHO Department of Global HIV, Hepatitis and STI Programmes \ncoordinated the guideline development process, which was informed by the WHO Guideline \nSteering Group composed of staff members from the Department of Sexual and Reproductive \nHealth, De",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "An annex describing how the CAB-LA guideline was developed under WHO guideline standards and Guideline Review Committee oversight, coordinated by the Department of Global HIV, Hepatitis and STI Programmes. It outlines the systematic review of safety and efficacy, supplementary evidence on values, costs and feasibility, and how the Guideline Development Group reached its recommendation. The annex closes with contact details and the ISBN.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360869/blocks/figure-img-p040-1",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 40,
      "pageEnd": 40,
      "target": "../images/img-p040-1.webp",
      "narrative": "draft",
      "content": "An ISBN barcode with the number 9789240054097 printed above and below the bars.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    }
  ]
}
